Altimmune, Inc. (ALT) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Altimmune Second Quarter 2025 Financial Results Conference Call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message, but your hand is raised. As a reminder, this call is being recorded. I'll now introduce your host for today's conference call, Lee Roth. President of Burns MacLennan, Investor Relations Advisor to Altimmune. Lee, you may begin. Thanks, Olivia. Good morning, everyone. Once again, thank you for joining us for the Altimmune Second Quarter 2025 Financial Result and Business Update Conference Call. On today's call, you'll hear from Dr. Vipin Garg, our Chief Executive Officer, Dr. Scott Harris, our Chief Medical Officer, and Greg Weaver, our Chief Financial Officer. Dr. Scott Roberts, our chief scientific officer, and Ray Jort, our chief business officer, will join us for the Q&A. Our second quarter 2025 financial results and corporate update press release was issued earlier this morning, and it can be found on the investor relations section of the Altamune website. Before we begin, I'd like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Security Mitigation Reform Act of 1995. All too many cautions that these forward-looking statements are subject to risks and uncertainties, and these could cause our actual results to differ materially from those indicated. For a full review of the risk factors that could affect the company's future results and operations, we ...